DGX Quest Diagnostics
Updated
Healthcare · Services-Medical Laboratories
Quest Diagnostics (DGX) is a healthcare company in the Services-Medical Laboratories industry, with a market capitalization of $26.4 billion. Shares last traded at $239.37, 3.1% below their 52-week high. Over the past year the stock is up 33.3%. DGX trades at a price-to-earnings ratio of 24.88, below the Services-Medical Laboratories median of 26.82. Net profit margin is 9.2%, above the peer median of -5.4%. Revenue grew 11.8% year over year. The shares yield 1.4% in dividends.
Performance
Chart
Full chart →Daily candles · volume · SMA(20)/SMA(50) · Databento EQUS.MINI.
Technicals
Financials
Latest reported annual period ending 2026-06-30 · SEC EDGAR/XBRL.
DGX Dividend History
| Fiscal year end | Total dividends paid | Per share* | Payout ratio |
|---|---|---|---|
| 2025-12-31 | $353M | $3.12 | 36% |
| 2024-12-31 | $331M | $2.93 | 38% |
| 2023-12-31 | $314M | $2.78 | 37% |
| 2022-12-31 | $305M | $2.58 | 32% |
| 2021-12-31 | $309M | $2.41 | 15% |
| 2020-12-31 | $297M | $2.18 | 21% |
| 2019-12-31 | $286M | $2.10 | 33% |
| 2018-12-31 | $266M | $1.91 | 36% |
| 2017-12-31 | $247M | $1.76 | 32% |
| 2016-12-31 | $223M | $1.57 | 35% |
| 2015-12-31 | $212M | $1.46 | 30% |
| 2014-12-31 | $187M | $1.29 | 34% |
*Per share derived as total dividends paid ÷ weighted diluted shares (SEC EDGAR/XBRL annual cash-flow facts). Reported history — not a forecast of future dividends.
Compare payers on the highest-dividend-yield screener.
Recent earnings
| Period | EPS (diluted) | Reported |
|---|---|---|
| Q2 2026 | $5.08 | 2026-07-23 |
| Q1 2026 | $2.24 | 2026-04-22 |
| FY 2025 | $8.75 | 2026-02-26 |
| Q3 2025 | $6.57 | 2025-10-21 |
| Q2 2026 | $4.41 | 2026-07-23 |
| Q1 2026 | $1.94 | 2026-04-22 |
Services-Medical Laboratories peers
DGX vs 14 industry peers (Services-Medical Laboratories), by market cap. Updated
| NTRA | Natera, Inc. | $47.2B | -245.26 | 17.43 | -7.1% | +0.66% |
| LH | Labcorp | $26.9B | 26.82 | 1.87 | 7.0% | -0.07% |
| DGX | Quest Diagnostics | $26.4B | 24.88 | 2.29 | 9.2% | -0.58% |
| GH | Guardant Health, Inc. | $21.6B | -47.65 | 18.26 | -38.3% | -1.23% |
| CAI | Caris Life Sciences, Inc. | $7.2B | 68.06 | 7.23 | 10.6% | +2.14% |
| RDNT | Radnet, Inc. | $5.9B | -278.18 | 2.59 | -0.9% | -1.36% |
| CELC | Celcuity Inc. | $4.7B | -20.82 | — | — | +0.06% |
| BLLN | Billiontoone, Inc. | $4.6B | 121.86 | 11.56 | 9.5% | +3.64% |
| GRAL | Grail, Inc. | $3.6B | -9.19 | — | — | +0.03% |
| VCYT | Veracyte, Inc. | $3.6B | 31.35 | 6.39 | 20.4% | -0.65% |
| CDNA | Caredx, Inc. | $2.6B | 23.22 | 5.63 | 24.2% | +0.44% |
| PSNL | Personalis, Inc. | $1.8B | -16.77 | — | — | +0.51% |
| FTRE | Fortrea Holdings Inc. | $1.8B | -20.77 | 0.66 | -3.2% | +1.47% |
| LMRI | Lumexa Imaging Holdings, Inc. | $1.1B | — | — | — | -1.53% |
Source: SEC EDGAR (fundamentals/EPS/dividends) · Databento EQUS.MINI (prices) · market cap & yield computed by tradmap. Informational only — not financial advice.